- Home
- FLNC vs NVCR Comparison
FLNC vs NVCR Comparison
Compare FLNC & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNC
- NVCR
- Stock Information
- Founded
- FLNC 2018
- NVCR 2000
- Country
- FLNC United States
- NVCR Jersey
- Employees
- FLNC N/A
- NVCR N/A
- Industry
- FLNC Industrial Machinery/Components
- NVCR Medical/Dental Instruments
- Sector
- FLNC Miscellaneous
- NVCR Health Care
- Exchange
- FLNC Nasdaq
- NVCR Nasdaq
- Market Cap
- FLNC 2.4B
- NVCR 1.8B
- IPO Year
- FLNC 2021
- NVCR 2015
- Fundamental
- Price
- FLNC $22.01
- NVCR $17.49
- Analyst Decision
- FLNC Buy
- NVCR Buy
- Analyst Count
- FLNC 17
- NVCR 5
- Target Price
- FLNC $27.35
- NVCR $26.60
- AVG Volume (30 Days)
- FLNC 1.3M
- NVCR 1.3M
- Earning Date
- FLNC 11-26-2024
- NVCR 10-30-2024
- Dividend Yield
- FLNC N/A
- NVCR N/A
- EPS Growth
- FLNC N/A
- NVCR N/A
- EPS
- FLNC N/A
- NVCR N/A
- Revenue
- FLNC $2,143,395,000.00
- NVCR $549,964,000.00
- Revenue This Year
- FLNC $27.28
- NVCR $16.23
- Revenue Next Year
- FLNC $44.10
- NVCR $6.09
- P/E Ratio
- FLNC N/A
- NVCR N/A
- Revenue Growth
- FLNC 7.87
- NVCR 8.33
- 52 Week Low
- FLNC $12.74
- NVCR $10.87
- 52 Week High
- FLNC $27.80
- NVCR $24.74
- Technical
- Relative Strength Index (RSI)
- FLNC 53.21
- NVCR 43.24
- Support Level
- FLNC $20.00
- NVCR $15.61
- Resistance Level
- FLNC $21.65
- NVCR $17.31
- Average True Range (ATR)
- FLNC 0.96
- NVCR 1.29
- MACD
- FLNC -0.08
- NVCR 0.05
- Stochastic Oscillator
- FLNC 65.79
- NVCR 11.59
About FLNC Fluence Energy Inc.
Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.